Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI
Low-dose Ticagrelor in Chinese ACS Patients Undergoing PCI
Dual Antiplatelet Therapy (DAPT) with aspirin and P2Y12 receptor inhibitor remains a
 cornerstone in the secondary prevention of coronary artery disease (CAD). Clopidogrel is one
 of the most commonly used antithrombotic agent that inhibits the platelet P2Y(12) adenosine
 diphosphate (ADP) receptor.

 Ticagrelor is an oral, reversibly-binding, direct-acting P2Y12 receptor antagonist used
 clinically for the prevention of atherothrombotic events in patients with acute coronary
 syndromes (ACS). Guideline recommendations on the use of dual antiplatelet therapy have been
 formulated that ticagrelor 90 mg twice daily plus aspirin in preference to clopidogrel 75mg
 daily plus aspirin for ACS patients. The previous studies have reported that half-dose
 ticagrelor had the similar inhibitory effect on platelet aggregation as the standard-dose
 ticagrelor, which was significantly stronger than that in the clopidogrel group. One-quarter
 standard-dose ticagrelor provided greater degree of platelet inhibition than standard dose
 clopidogrel in Chinese patients with stable CAD. But the effectiveness and safety of low-dose
 ticagrelor remain yet not very clearly in Chinese patients with acute coronary syndrome
 undergoing percutaneous coronary intervention.
Inclusion Criteria:

 -  After half-dose ticagrelor (loading dose 90mg, and then 45mg bidpo.) treatment for 3
 days, the platelet aggregation is effectively inhibited by light transmission
 aggregometry method and thromboela-stogram.

 -  planned to undergo PCI recently

 -  planned to DAPT for 1 year after PCI

 Exclusion Criteria:

 -  taken adenosine diphosphate (ADP) receptor antagonists within 2 weeks

 -  Platelet count <100g/L;

 -  A history of bleeding tendency;

 -  Aspirin, ticagrelor or clopidogrel allergies;

 -  Severe liver injury.